Fig 1.
CSFE-based assay for detecting Gag-specific T-cell proliferation.
A. The gating strategy involved a FS-SS gate for viable lymphocytes, with the exclusion of FSClo-SSCint apoptotic cells; a FS-CD3 gate for CD3+ lymphocytes; CD4+CD8- and CD4-CD8+ gates for CD4 and CD8 T lymphocytes, respectively; a CFSElow gate for proliferating CD4 and CD8 T lymphocytes. For the 79 patients studied, SI (panel B) and net difference in CFSElow percentages (panel C) in response to the Gag peptide pool and SEB, used as positive control, are shown. For 17 patients, the assay was carried out against both the Gag peptide pool and p24gag protein (used as described in [47]); SI values are shown for CD4 and CD8 T-cell responses (panels D and E, respectively). On panels B to E, the red bars indicate the positivity threshold.
Table 1.
Black ethnicity was strongly associated with Gag-specific CD4 and CD8 T-cell proliferation.
Table 2.
Analyses of association between HIV disease history and Gag-specific CD4 T-cell proliferation in aviremic patients.
Table 3.
Analysis of association between HIV disease history and Gag-specific CD8 T-cell proliferation in aviremic patients.
Table 4.
Analyses of association between HIV disease history and Gag-specific CD8 T-cell proliferation in viremic patients.